Horacio Plotkin Net Worth

The estimated Net Worth of Horacio Plotkin is at least $106 Thousand dollars as of 12 December 2014. Horacio Plotkin owns over 2,100 units of Retrophin stock worth over $6,424 and over the last 12 years Horacio sold RTRX stock worth over $99,727.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Horacio Plotkin RTRX stock SEC Form 4 insiders trading

Horacio has made over 3 trades of the Retrophin stock since 2013, according to the Form 4 filled with the SEC. Most recently Horacio sold 2,100 units of RTRX stock worth $21,147 on 12 December 2014.

The largest trade Horacio's ever made was selling 8,333 units of Retrophin stock on 17 November 2014 worth over $78,580. On average, Horacio trades about 2,106 units every 81 days since 2013. As of 12 December 2014 Horacio still owns at least 91,767 units of Retrophin stock.

You can see the complete history of Horacio Plotkin stock trades at the bottom of the page.

What's Horacio Plotkin's mailing address?

Horacio's mailing address filed with the SEC is C/O RETROPHIN, INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK, NY, 10017.

Insiders trading at Retrophin

Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer, and Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.

What does Retrophin do?

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Complete history of Horacio Plotkin stock trades at Retrophin

Retrophin executives and stock owners

Retrophin executives and other stock owners filed with the SEC include:

• Eric Dube,
  President, Chief Executive Officer, Director
• Elizabeth Reed,
  Senior Vice President, General Counsel and Corporate Secretary
• Noah Rosenberg,
  Chief Medical Officer
• Peter Heerma,
  Chief Commercial Officer
• William Rote,
  Senior Vice President and Head of Research and Development
• Laura Clague,
  Chief Financial Officer, Senior Vice President
• Stephen Aselage,
  Director
• Sandra Poole,
  Independent Director
• Gary Lyons,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• Jeffrey Meckler,
  Independent Director
• John Orwin,
  Independent Director
• Roy Baynes,
  Independent Director
• Ron Squarer,
  Independent Director
• Suzanne Bruhn,
  Independent Director
• Neil F. Mc Farlane,
  Chief Operating Officer
• Jensen Margaret E Valeur,
  General Counsel
• John W Kozarich,
  Director
• Alvin Shih,
  EVP of Research & Development
• Cornelius E Golding,
  Director
• Steve Aselage,
  Director
• Martin Shkreli,
  Chief Executive Officer
• Steven Gary Richardson,
  Director
• Horacio Plotkin,
  Chief Medical Officer
• Jeffrey Paley,
  Director
• Marc L Panoff,
  Chief Financial Officer